Atika Capital Management LLC Purchases New Position in Boston Scientific Co. (NYSE:BSX)

Atika Capital Management LLC purchased a new stake in shares of Boston Scientific Co. (NYSE:BSX - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 85,200 shares of the medical equipment provider's stock, valued at approximately $7,610,000.

A number of other large investors have also added to or reduced their stakes in BSX. Benjamin Edwards Inc. increased its position in Boston Scientific by 5,065.7% during the third quarter. Benjamin Edwards Inc. now owns 14,154 shares of the medical equipment provider's stock valued at $1,186,000 after acquiring an additional 13,880 shares during the last quarter. HighTower Advisors LLC raised its stake in Boston Scientific by 28.2% in the third quarter. HighTower Advisors LLC now owns 109,978 shares of the medical equipment provider's stock worth $9,241,000 after buying an additional 24,180 shares in the last quarter. IHT Wealth Management LLC grew its stake in Boston Scientific by 26.3% in the third quarter. IHT Wealth Management LLC now owns 5,323 shares of the medical equipment provider's stock valued at $447,000 after purchasing an additional 1,108 shares during the last quarter. Quarry LP boosted its stake in Boston Scientific by 81.4% in the third quarter. Quarry LP now owns 780 shares of the medical equipment provider's stock valued at $65,000 after acquiring an additional 350 shares in the last quarter. Finally, Two Sigma Advisers LP boosted its holdings in Boston Scientific by 41.6% in the third quarter. Two Sigma Advisers LP now owns 508,460 shares of the medical equipment provider's stock worth $42,609,000 after acquiring an additional 149,500 shares in the last quarter. Institutional investors own 89.07% of the company's stock.

Boston Scientific Trading Up 1.1 %

NYSE:BSX traded up $1.00 during trading hours on Friday, reaching $93.64. 3,017,486 shares of the stock were exchanged, compared to its average volume of 6,331,663. Boston Scientific Co. has a twelve month low of $66.80 and a twelve month high of $107.17. The business has a 50-day moving average of $100.73 and a two-hundred day moving average of $93.95. The company has a market capitalization of $138.50 billion, a price-to-earnings ratio of 74.97, a PEG ratio of 2.79 and a beta of 0.73. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, beating analysts' consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. On average, equities analysts predict that Boston Scientific Co. will post 2.85 EPS for the current year.

Insiders Place Their Bets

In related news, EVP Jeffrey B. Mirviss sold 4,675 shares of the company's stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $104.25, for a total transaction of $487,368.75. Following the sale, the executive vice president now directly owns 28,454 shares in the company, valued at approximately $2,966,329.50. This represents a 14.11 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $101.80, for a total transaction of $1,762,463.40. Following the completion of the transaction, the executive vice president now owns 5,502 shares of the company's stock, valued at $560,103.60. This represents a 75.88 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 133,183 shares of company stock worth $13,948,476 over the last 90 days. Corporate insiders own 0.50% of the company's stock.

Analysts Set New Price Targets

A number of analysts have commented on BSX shares. UBS Group lifted their price target on Boston Scientific from $105.00 to $130.00 and gave the stock a "buy" rating in a research report on Friday, February 7th. Royal Bank of Canada increased their price target on Boston Scientific from $105.00 to $116.00 and gave the stock an "outperform" rating in a research report on Thursday, February 6th. Deutsche Bank Aktiengesellschaft raised shares of Boston Scientific from a "hold" rating to a "buy" rating and set a $108.00 target price for the company in a research note on Friday, January 10th. Barclays increased their target price on Boston Scientific from $111.00 to $118.00 and gave the company an "overweight" rating in a report on Monday, February 10th. Finally, Stifel Nicolaus boosted their price target on Boston Scientific from $100.00 to $115.00 and gave the stock a "buy" rating in a research report on Thursday, February 6th. Two investment analysts have rated the stock with a hold rating, twenty-one have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $109.04.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.